A vaccine scientist tells the story of a first date that turned into a lesson about vaccine doubt, long before the COVID ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

In addition to long-standing engineering partnerships with Columbia University and Dartmouth College, Hobart and William ...

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was ...

Building on recent successes, scientists are focused on a promising new frontier: sending tiny particles into the body to ...

The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

I have long had a fascination with the grit it takes to be a Manhattan developer. After all, I taught market analysis to a class of approximately 150 graduate students in Columbia’s Master of Science ...

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value.

A U.S. appeals court on Thursday upheld a ruling for AstraZeneca against allegations that its ​blockbuster lung-cancer drug Tagrisso infringed patents owned by ‌Pfizer subsidiary Wyeth.